<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882750</url>
  </required_header>
  <id_info>
    <org_study_id>L399</org_study_id>
    <nct_id>NCT02882750</nct_id>
  </id_info>
  <brief_title>Effect on Patient Reported Outcomes of VATS and SABR (LILAC)</brief_title>
  <acronym>LILAC</acronym>
  <official_title>Curative Treatment Modalities of Early Stages Non-Small Cell Lung Cancer: Effect on Patient Reported Outcomes of Video Assisted Thoracoscopic (VATS) Resection and Stereotactic Ablative Body Radiotherapy (SABR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yorkshire Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection&#xD;
      and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with&#xD;
      this information the Shared Decision Making (SDM) process.&#xD;
&#xD;
      300 consecutive patients will be followed up from prior the treatment to 12 months&#xD;
      afterwards, administering multiple questionnaires (EORTC QLQ C-30 and LC-13, PSQ-18, Decision&#xD;
      Self-Efficacy Scale) by a remote web-based system.&#xD;
&#xD;
      Deliverable:&#xD;
&#xD;
        1. Differences after VATS resections or SABR in terms of physical and psychological&#xD;
           symptoms, quality of life and satisfaction&#xD;
&#xD;
        2. Patient perspectives of the Shared Decision Making Process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Methods&#xD;
&#xD;
           Aim and Objectives&#xD;
&#xD;
           This study aims to describe the trajectory of lung cancer patients HRQoL, symptoms and&#xD;
           functions following VATS or SABR treatment for Stage I-II NSCLC and to determine the&#xD;
           feasibility and patient acceptability of online self-reporting of PROMs.&#xD;
&#xD;
           Specific objectives of the study include:&#xD;
&#xD;
             -  To compare changes before and after treatment of patient reported outcomes (HRQOL&#xD;
                and Patient Satisfaction) after VATS lung resections or SABR in early stage lung&#xD;
                cancer patients.&#xD;
&#xD;
             -  To correlate clinical outcomes (complications and AEs) with Quality of Life in&#xD;
                order to find objective predictors of major decline in patient reported outcomes.&#xD;
&#xD;
             -  To identify specific factors, which have influenced the personal choice between the&#xD;
                treatments (Decision Self-Efficacy Scale)&#xD;
&#xD;
             -  Establish recruitment and attrition rates and adherence to PROMs reporting during&#xD;
                the study&#xD;
&#xD;
             -  To describe patient choice of electronic vs paper questionnaires&#xD;
&#xD;
             -  To explore implementation issues through patient and staff interview.&#xD;
&#xD;
        2. Design&#xD;
&#xD;
      This is an observational prospective longitudinal study with repeated measures (PROMs),&#xD;
      employing a convenience sample of consecutive patients planned to have VATS resections or&#xD;
      SABR for stages I-II of NSCLC. Outcomes measures will be collected prior to treatment and&#xD;
      1,3,6,12 months afterwards, administering the questionnaires by the remote web-based system.&#xD;
      Paper administration will be offered to patients without Internet access.&#xD;
&#xD;
      Sample size considerations&#xD;
&#xD;
      Last year 100 pre-surgical quality of life questionnaires have been collected in 5 months&#xD;
      from outpatients' clinic at Leeds Cancer Centre (LCC). For longitudinal studies involving&#xD;
      regular PROMs, the investigators typically see 70% consent rate and 30-35% attrition over 3&#xD;
      months24. Therefore the investigators expectations are to be able to recruit 200 VATS and 50&#xD;
      SABR patients recruiting over 12 months with 12 months of follow-up.&#xD;
&#xD;
      In order to detect a minimum difference of 10% from the baseline value and standard deviation&#xD;
      of the EORTC QLQ-C30 Global Health Scale scale (as measured in our historical cohort of 115&#xD;
      anatomic lung resections), with a alfa level of 0.05 and statistical power of 90%, a sample&#xD;
      size of 115 patients in the surgical arm was estimated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Reported Outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life (EORTC QLQ-C30 and LC13 questionnaire)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision self-efficacy scale</measure>
    <time_frame>3 months</time_frame>
    <description>Patient perspectives of the Shared Decision Making Process.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptability</measure>
    <time_frame>12 months</time_frame>
    <description>Patient acceptability explored through interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Acceptability</measure>
    <time_frame>12 months</time_frame>
    <description>clinician acceptability explored through interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction</measure>
    <time_frame>1 month</time_frame>
    <description>patients satisfaction of the care received (PSQ-18 Patient satisfaction questionnaire)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">244</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Surgical Patients</arm_group_label>
    <description>Early stage NSCLC patients submitted to Surgical Resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SABR Patients</arm_group_label>
    <description>Early stage NSCLC patients submitted to SABR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ-C30 (version 3.0).</intervention_name>
    <description>Quality of Life Questionnaire</description>
    <arm_group_label>SABR Patients</arm_group_label>
    <arm_group_label>Surgical Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PS Q18</intervention_name>
    <description>Patients Satisfaction Questionnaire</description>
    <arm_group_label>SABR Patients</arm_group_label>
    <arm_group_label>Surgical Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decision Self-Efficacy Scale</intervention_name>
    <description>Questionnaire</description>
    <arm_group_label>SABR Patients</arm_group_label>
    <arm_group_label>Surgical Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Early stage Non-Small Cell Lung Cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and over.&#xD;
&#xD;
          -  Diagnosis of NSCLC either from histology or MDT/Tumour Board agreement on &gt;95%&#xD;
             likelihood of diagnosis based on radiological evidence or both.&#xD;
&#xD;
          -  Decision for either surgery or SABR&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
          -  Able to understand the language of the questionnaire.&#xD;
&#xD;
          -  There will be no limit on performance status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced diseases (III-IV stages).&#xD;
&#xD;
          -  Patient included in other HRQoL study, which may increase patient burden and bias the&#xD;
             answer of the questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Galina Velikova</investigator_full_name>
    <investigator_title>Prof of Clinical Oncology</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>VATS</keyword>
  <keyword>SABR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

